Oncotelic Therapeutics Inc. OTLC Archives

WednesdayJul 15, 2026 2:43 pm

QualityStocksNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Brings AI and Robotics Together in New Platform

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed the company’s launch of an AI-powered manufacturing services platform designed to help emerging biotechnology companies overcome one of the industry’s biggest challenges: accessing full GMP infrastructure. “The platform combines Oncotelic’s proprietary PDAOAI(TM) architecture with digital manufacturing technologies and intelligent robotics developed in collaboration with TechForce Robotics, the company’s strategic robotics and automation partner. The goal is not simply to apply AI to drug discovery, but to bring it into the manufacturing workflows that determine whether a therapy moves efficiently from development toward commercialization.” Already deployed at Oncotelic’s GMP-certified SAPU manufacturing facility to…

ThursdayJul 09, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Targets Biotech’s Manufacturing Bottleneck with AI-Powered GMP Platform

Oncotelic has launched an AI-powered GMP manufacturing services platform that integrates its PDAOAI(TM) architecture, digital batch records, and intelligent robotics built with partner TechForce Robotics The platform targets emerging biotechs, CDMOs, cell and gene therapy developers, and radiopharmaceutical manufacturers that cannot justify building full GMP infrastructure in-house The same AI-GMP capabilities already run inside Oncotelic's SAPU manufacturing base, positioning the launch as both a pipeline accelerator and a potential new revenue line For emerging biotechnology companies, the road from promising science to clinical execution often breaks down in the same place: manufacturing. Discovery can begin in a university lab, a…

WednesdayJun 24, 2026 1:51 pm

QualityStocksNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Eyes Opportunity Through AI and Pharmaceutical Automation

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed the company’s efforts to move beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. The publication reads, “Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments… At the core of this pivot is Oncotelic’s proprietary PDAOAI platform, an AI-driven system designed to improve compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing expertise,…

TuesdayJun 23, 2026 10:30 am

The $410 Billion Drug Delivery Revolution: Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation

The rapidly expanding nanomedicine and advanced drug-delivery market is attracting growing attention as pharmaceutical companies seek ways to improve therapeutic performance without relying solely on costly new drug discovery programs. By addressing challenges such as poor bioavailability, inconsistent pharmacokinetics and limited tumor penetration, nanotechnology-based delivery systems may unlock additional value from existing oncology drugs. Oncotelic Therapeutics' Deciparticle(TM) platform and Sapu003 program illustrate how innovative drug delivery approaches could help reshape the future of cancer treatment. The search for new cancer therapies has traditionally focused on discovering entirely new drug candidates. While this approach has produced important breakthroughs, it is also…

ThursdayJun 18, 2026 9:00 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Launches AI-Powered GMP Manufacturing Services Platform at BIO 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform combines the company's PDAOAI™ technology with advanced robotics provided through its collaboration with TechForce Robotics to support pharmaceutical, biotechnology and advanced therapeutics companies seeking to modernize manufacturing operations through AI-driven workflows, digital quality systems and intelligent automation. Oncotelic said the platform is designed to support electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions and process monitoring. The company will also showcase progress with its Deciparticle™ nanomedicine platform, including…

WednesdayJun 17, 2026 9:00 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances AI-Powered GMP Manufacturing Platform

Oncotelic Therapeutics (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing commercialization of an AI-powered good manufacturing practices manufacturing services platform at SAPU Bio, the company's 45%-owned sterile injectable cGMP manufacturing joint venture. The Phase 2 deployment expands the capabilities of Oncotelic's proprietary PDAOAI(TM) platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement. The company said the integrated platform combines PDAOAI(TM) with TechForce's autonomous robotic systems to support intelligent pharmaceutical manufacturing and create potential opportunities in software licensing, automation deployment, manufacturing partnerships…

MondayJun 08, 2026 9:20 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Showcase AI Drug Discovery Platform at Qdrant Vector Space Day 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced that its proprietary PDAOAI(TM) drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026 in San Francisco on June 11. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development. The presentation will highlight several innovations underpinning the platform, including a proprietary "manifold folding" technique designed to improve semantic…

FridayJun 05, 2026 10:30 am

Oncotelic Therapeutics Inc. (OTLC) Combines Nanomedicine, AI, and Robotics to Advance Precision Oncology and Rare Disease Innovation

OTLC continues to advance its Deciparticle nanomedicine platform, with expanding international development initiatives supporting future therapeutic and commercial opportunities. The company's PDAOAI ecosystem now incorporates 28 million scientific abstracts and is being deployed into real-world pharmaceutical automation applications through TechForce Robotics. The company is leveraging AI, nanomedicine, and automation to accelerate therapies for cancer and rare diseases. Oncotelic Therapeutics (OTCQB: OTLC) is strategically placing itself at the nexus of precision oncology, advanced automation, and artificial intelligence. Through its PDAOAI artificial intelligence ecosystem, Deciparticle(TM) nanomedicine platform, and emerging robotics initiatives, the company is quickly building an integrated technology portfolio built to…

ThursdayJun 04, 2026 10:15 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Drug-Delivery Market Growth

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in a BioMedWire editorial examining growing investor interest in platform biotech companies as the global drug-delivery market advances toward an estimated $410 billion opportunity. The editorial highlights increasing industry focus on overcoming challenges related to drug penetration, tumor targeting, therapeutic resistance and maintaining consistent intratumoral exposure, while spotlighting Oncotelic’s Sapu003 and Deciparticle platform as examples of nanotechnology-driven drug-delivery approaches designed to enhance the clinical utility of existing therapies through improved pharmacokinetics and delivery performance. To view the full press release, visit https://ibn.fm/laaQ6 About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical…

WednesdayJun 03, 2026 9:50 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial exploring how biotechnology companies are increasingly leveraging advanced drug-delivery technologies, nanotechnology platforms and artificial intelligence to enhance existing therapies and expand treatment opportunities. The article highlights Oncotelic’s Sapu003 program, Deciparticle(TM) platform and PDAOAI initiative as part of a broader industry trend toward scalable, multi-application biotechnology platforms capable of supporting oncology and rare disease programs. The editorial also discusses developments from CytoDyn Inc. (OTCQB: CYDY), which is advancing leronlimab for oncology indications; Revolution Medicines Inc. (NASDAQ: RVMD), which reported positive Phase 3 results for daraxonrasib in pancreatic cancer; Moderna Inc. (NASDAQ:…

Site Search

Company Search

Tag: Oncotelic Therapeutics Inc. OTLC